Company intelligence / Profile preview

AgPlenus

Ownership: Private
Employees: ~18
Development stage: Preclinical

Overview

AgPlenus has validated several novel targets in-planta and discovered active hits that have been optimized for efficacy. Their most advanced programs include a new mode-of-action fungicide targeting Septoria with successful field trial results. No clinical/commercial products yet.

Therapeutic areas: OtherInfectious Diseases
Modalities: Small moleculeAI-driven compound discoverySynthetic chemistry (for crop protection agents)
Industry: Agriculture & AgTech

Partnerships

BayerCorteva

Beyond the preview

Go deeper on AgPlenus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AgPlenus.

Explore the full profile